Medincell SA (MEDCL)

Currency in EUR
17.19
-0.13(-0.75%)
Real-time Data·
MEDCL Scorecard
Full Analysis
Analysts do not anticipate the company will be profitable this year
Earnings results expected in 5 days
MEDCL is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
17.1017.46
52 wk Range
12.0019.00
Key Statistics
Prev. Close
17.32
Open
17.37
Day's Range
17.1-17.46
52 wk Range
12-19
Volume
30.96K
Average Volume (3m)
83.06K
1-Year Change
-5.36%
Book Value / Share
-0.49
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
MEDCL Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
22.77
Upside
+32.47%
Members' Sentiments
Bearish
Bullish
ProTips
Liquid assets exceed short term obligations

Medincell SA News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Sell
Moving Averages
Buy

Medincell SA Company Profile

MedinCell S.A., a pharmaceutical company, develops long acting injectables in various therapeutic areas in France. It develops solutions based on BEPO, a long-acting injectable technology; and offers UZEDY (mdc-IRM) for the treatment of schizophrenia in adults. The company’s products in development include mdc-CWM, a sustained-release formulation of celecoxib in Phase III trials for use in the treatment of reduction of postoperative pain and inflammation; and mdc-TJK, a subcutaneous injection that is in Phase III clinical trials for use in the treatment of schizophrenia. Its product candidates in preclinical trials include mdc-WWM for contraception; and mdc-STM for malaria. MedinCell S.A. was incorporated in 2003 and is headquartered in Jacou, France.

Employees
131
Market
France

Compare MEDCL to Peers and Sector

Metrics to compare
MEDCL
Peers
Sector
Relationship
P/E Ratio
−30.9x16.1x−0.6x
PEG Ratio
−1.06−0.050.00
Price/Book
−34.9x2.8x2.6x
Price / LTM Sales
20.6x3.2x3.3x
Upside (Analyst Target)
27.0%85.6%39.1%
Fair Value Upside
Unlock14.2%5.4%Unlock

Analyst Ratings

8 Buy
0 Hold
0 Sell
Ratings:
8 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 22.77
(+32.47% Upside)

Earnings

Latest Release
Jun 17, 2025
EPS / Forecast
-0.17 / -0.17
Revenue / Forecast
4.90M / 5.70M
EPS Revisions
Last 90 days

MEDCL Income Statement

People Also Watch

3.828
VLS
-0.10%
261.20
ESLX
-0.84%
69.40
ABVX
+1.02%
65.78
TEPRF
-2.23%
23.40
STMPA
-1.64%

FAQ

What Stock Exchange Does Medincell Trade On?

Medincell is listed and trades on the Paris Stock Exchange stock exchange.

What Is the Stock Symbol for Medincell?

The stock symbol for Medincell is "MEDCL."

What Is the Medincell Market Cap?

As of today, Medincell market cap is 568.62M.

What Is Medincell's Earnings Per Share (TTM)?

The Medincell EPS (TTM) is -0.62.

When Is the Next Medincell Earnings Date?

Medincell will release its next earnings report on 02 Sept 2025.

From a Technical Analysis Perspective, Is MEDCL a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Medincell Stock Split?

Medincell has split 0 times.

How Many Employees Does Medincell Have?

Medincell has 131 employees.

What is the current trading status of Medincell (MEDCL)?

As of 29 Aug 2025, Medincell (MEDCL) is trading at a price of 17.19, with a previous close of 17.32. The stock has fluctuated within a day range of 17.10 to 17.46, while its 52-week range spans from 12.00 to 19.00.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.